Welcome to our dedicated page for Nexgel SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NEXGEL, Inc. (NASDAQ: NXGL) SEC filings page brings together the company’s official regulatory documents, giving investors direct insight into its hydrogel-focused healthcare and consumer products business. As a Delaware corporation listed on NASDAQ, NEXGEL files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements such as its definitive proxy on Schedule 14A.
In these filings, NEXGEL details its operations in ultra-gentle, high-water-content hydrogel products, its contract manufacturing relationships with consumer healthcare companies, and its portfolio of brands including SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Financial statements and accompanying notes explain revenue from contract manufacturing and branded products, gross profit, operating expenses, and net loss attributable to NEXGEL stockholders.
Current reports on Form 8-K provide timely disclosure of material events, such as quarterly financial results, the spin-off of a portion of the drug delivery program into NexGelRx, changes in executive leadership, and decisions by the board of directors regarding special meetings or capital structure proposals. Proxy materials, including the company’s definitive proxy statement for a special meeting of stockholders, describe matters submitted to shareholder vote, such as proposed amendments to the certificate of incorporation.
Through this page, users can also review filings related to equity offerings, warrants, and other securities matters referenced in NEXGEL’s disclosures. Real-time updates from the SEC’s EDGAR system ensure that new NXGL filings appear promptly, while AI-powered summaries help explain the key points of lengthy documents, including complex sections on non-GAAP financial measures, risk factors, and governance provisions.
For those analyzing NXGL, this SEC filings archive offers a structured view of how NEXGEL reports its business, finances, and corporate actions over time, directly from its official submissions to regulators.
NexGel, Inc. announced that its Board of Directors has canceled the Special Meeting of Stockholders that had been scheduled for November 26, 2025. The special meeting had been called for stockholders to vote on a proposal to amend the company’s Amended and Restated Certificate of Incorporation to increase the authorized shares of common stock, par value $0.001 per share, from 25,000,000 to 1,000,000,000. By canceling the meeting, the Board and the company state that they will not be pursuing stockholder approval of this proposed increase in authorized common shares.
NexGel, Inc. furnished an update via Form 8-K. The company provided a press release reporting results for the quarter ended September 30, 2025 and began using a new investor presentation. These materials were furnished under Items 2.02 and 7.01 and include Exhibit 99.1 (press release) and Exhibit 99.2 (investor presentation). The company stated the furnished information shall not be deemed filed for purposes of Section 18 of the Exchange Act.
NexGel, Inc. (NXGL) filed its Q3 2025 report, showing steady quarterly results and a continued focus on consumer brands alongside contract manufacturing. Revenue for the quarter was $2.934 million versus $2.940 million a year ago, while nine‑month revenue rose to $8.625 million from $5.647 million. Q3 gross profit was $1.243 million. The net loss attributable to stockholders was $653,000, or $0.08 per share, an improvement from $693,000 (or $0.11) last year.
The company disclosed substantial doubt about its ability to continue as a going concern. At September 30, cash was $938,000, alongside $920,000 of partnership restricted cash. Operating cash use for the nine months was $1.592 million, and working capital was $2.3 million. During Q3, NexGel raised equity proceeds of $963,000 by issuing 458,695 shares. Shares outstanding were 8,142,766 as of September 30, and 8,143,133 as of November 12, 2025.
Segment mix for Q3 included $1.918 million from consumer branded products and $907,000 from contract manufacturing.
NEXGEL (NXGL) reported an insider transaction on a Form 4. The Chief Executive Officer and Director sold 4,000 shares of common stock on 11/06/2025 at a $2.5211 weighted average price, pursuant to a Rule 10b5-1 trading plan.
Following the sale, the reporting person beneficially owns 367,692 shares, held directly. The price reflects multiple open-market sales within the $2.500–$2.5500 range.
NexGel, Inc. plans a special stockholder vote on an Authorized Share Increase. The proposal asks investors to approve—if and only if the Board later approves and implements—an amendment to raise authorized common stock from 25,000,000 to 1,000,000,000 shares, with total authorized capital increasing to 1,005,000,000 shares. The Board unanimously recommends a “FOR” vote.
The company cites future flexibility for capital raising, acquisitions, partnerships, and other corporate needs. Existing rights of common stock would remain the same, and preferred stock authorization stays at 5,000,000. The filing notes potential dilution if additional shares are issued in the future and acknowledges possible anti‑takeover effects, while stating the proposal is not in response to any control effort. Stockholders of record as of October 20, 2025 may vote; 8,142,766 common shares were outstanding as of that date.
NexGel, Inc. is asking stockholders to approve a major increase in authorized common shares—from 25,000,000 to 1,000,000,000—“if and only if” the Board later approves and implements the change. The vote will be held at 10:00 a.m. ET on November 26, 2025, at the company’s Langhorne, PA headquarters.
The Board unanimously recommends a “FOR” vote. The proposal requires the affirmative vote of a majority of total outstanding shares entitled to vote. Brokers have discretionary authority to vote on this proposal, and no appraisal rights apply.
The company cites future flexibility to raise capital, pursue acquisitions, joint ventures, and other corporate needs. The amendment itself has no immediate effect on ownership or voting power, but future issuances could dilute existing holders. As of October 20, 2025, shares outstanding were 8,142,766. If approved, the Board may effect the increase within twelve months by filing a Certificate of Amendment with Delaware.
NEXGEL, Inc. (NXGL) director Robert Henry Scott reported open-market sales under a Rule 10b5-1 plan. The earliest transaction date is 10/02/2025. He sold 825 shares on 10/02/2025 at $2.50 per share and 7,175 shares on 10/03/2025 at a weighted average price of $2.5502, reducing his direct holdings from 120,531 to 113,356 shares. The filing states the shares were originally purchased in the open market on 03/01/2024.
NEXGEL (NXGL) CEO and director Adam R. Levy disclosed open‑market sales executed under a Rule 10b5‑1 trading plan.
He sold 1,600 shares on 10/02/2025 at $2.5000 per share and 2,400 shares on 10/03/2025 at a weighted average price of $2.5497, with individual trades ranging from $2.5000 to $2.6100. After these transactions, he beneficially owned 371,692 shares.
Nexgel, Inc. (NXGL) filed a Form 144 reporting a proposed sale of 16,000 common shares with an aggregate market value of $40,000.00. The shares were originally acquired on 10/15/2019 as compensation from the issuer. The filing lists approximately 8,067,580 shares outstanding and names The Charles Schwab Corporation as the broker with an approximate sale date of 10/02/2025 on NASDAQ. The filer also reported a prior sale of 4,000 shares on 08/28/2025 for gross proceeds of $9,896.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
NEXGEL director Henry Scott Robert sold 7,697 shares of the company's common stock on 09/25/2025 under a pre-established Rule 10b5-1 trading plan at a weighted average price of $2.3579 per share. The shares were originally purchased on 03/01/2024. After the sale, the reporting person beneficially owns 121,356 shares, held directly. The filer notes the sale prices ranged from $2.3500 to $2.3900 and offers to provide a breakdown of shares sold at each price if requested.